Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Durect Corporation patents


Recent patent applications related to Durect Corporation. Durect Corporation is listed as an Agent/Assignee. Note: Durect Corporation may have other listings under different names/spellings. We're not affiliated with Durect Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "D" | Durect Corporation-related inventors


Oral pharmaceutical dosage forms

Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. ... Durect Corporation

Oral pharmaceutical dosage forms

Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.. . ... Durect Corporation

Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material

Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (hvlcm), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.. ... Durect Corporation

Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material

Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (hvlcm), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. ... Durect Corporation

Injectable, non-aqueous suspension with high concentration of therapeutic agent

An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. ... Durect Corporation

Oral pharmaceutical dosage forms

Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.. . ... Durect Corporation

Oral pharmaceutical dosage forms

Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. ... Durect Corporation

Sustained release small molecule drug formulation

An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having cmax to cmin ratio less than 200 and lag time less than 0.2.. . ... Durect Corporation

Controlled delivery system

The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. ... Durect Corporation

Compositions with a rheological modifier to reduce dissolution variability

The present disclosure provides compositions (e.g., extended release compositions) which exhibit a desirable pharmacokinetic profile of an active agent while providing reduced dissolution sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions are also provided.. ... Durect Corporation

Radiation-sterilized biodegradable drug delivery compositions

The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided.. ... Durect Corporation

Compositions with a rheological modifier to reduce dissolution variability

The present disclosure provides compositions (e.g., extended release compositions) which exhibit a desirable pharmacokinetic profile of an active agent while providing reduced dissolution sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions and formulations are also provided.. ... Durect Corporation

Biodegradable drug delivery composition

The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. ... Durect Corporation

Oral drug delivery system

Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.. . ... Durect Corporation

03/30/17 / #20170087086

Short duration depot formulations

Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.. ... Durect Corporation

01/19/17 / #20170014429

Uses of oxygenated cholesterol sulfates (ocs)

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (mods), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (ocs), e.g. ... Durect Corporation

01/12/17 / #20170007549

Transdermal delivery systems

Disclosed are bupivacaine transdermal delivery systems, and related methods.. . ... Durect Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Durect Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Durect Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###